Premium
Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis
Author(s) -
Sivera Piera,
Cesano Luigi,
Guerrasio Angelo,
Camaschella Clara,
Mazza Umberto
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb04750.x
Subject(s) - osteosclerosis , medicine , myelofibrosis , bone remodeling , bone marrow , haematopoiesis , myeloid , bone pain , gastroenterology , surgery , pathology , biology , stem cell , genetics
Summary We report a patient with agnogenic myeloid metaplasia associated with debilitating bone pain due to increased bone turnover and osteosclerosis. Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis. We suggest that diphosphonate therapy may be of value in patients with AMM and increased bone turnover.